GRI Bio
5 hedge funds and large institutions have $25.3K invested in GRI Bio in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
63% more capital invested
Capital invested by funds: $15.5K → $25.3K (+$9.81K)
25% more funds holding
Funds holding: 4 → 5 (+1)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$18.2K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.83K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$42 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $19.9K | +$18.2K | +436 | +376% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4.95K | +$3.83K | +92 | +204% |
|
3
BlackRock
New York
| $272 | – | – | – |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $151 | – | – | – |
|
|
5
Bank of America
Charlotte,
North Carolina
| $25 | +$42 | +1 | New |
|
GRI Hedge Fund Activity: Q2 2025 in Review
5 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q2 2025, worth a combined $25.3K — up 63% from $15.5K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GRI positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $18.2K.
- 5 institutional investors held GRI Bio (GRI) as of Q2 2025, up from 4 in Q1 2025.
- Funds reported $25.3K of GRI Bio stock for Q2 2025, up 63% quarter-over-quarter.
- 1 fund opened new GRI Bio positions in Q2 2025 and 0 closed out, a net change of +1 holder.
- The largest GRI Bio buyer in Q2 2025 was UBS Group, an estimated $18.2K added.
Based on aggregated 13F filings for Q2 2025.